MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD
February 09, 2024 19:30 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
The FDA has accepted Lykos Therapeutics' New Drug Application, supported by two decades of research incubated by MAPS, for MDMA-assisted therapy for PTSD.
PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development
February 09, 2024 08:10 ET
|
PharmAla Biotech
PharmAla signs all-cash agreement to consult for Red Light Holland
Optimi Announces Non-Brokered Private Placement
February 08, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Announces Non-Brokered Private Placement
Optimi Health To Host MDMA Educational Quality Assurance Webinar For Clinicians And Practitioners
February 06, 2024 07:30 ET
|
Optimi Health Corp.
Highlights: Optimi Chief Science and Quality Assurance experts to provide in-depth access into the Company’s safety and quality standards.Optimi experts will address critical inquiries which still...
PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
January 31, 2024 10:58 ET
|
PharmAla Biotech
PharmAla releases Profitable Q1 Interim Financial Statement, and will host investor webinar to discuss prominent changes to the business & FDA timelines
PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada
January 25, 2024 12:09 ET
|
PharmAla Biotech
PharmAla granted a Health Canada Controlled Drugs and Substances Dealer's License
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
January 24, 2024 09:35 ET
|
PharmAla Biotech
PharmAla recieved a new OTCQB ticker, MDXXF.
Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
January 19, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Health granted amendment to its Health Canada Controlled Drugs and Substances Licence.
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
January 08, 2024 08:55 ET
|
PharmAla Biotech
PharmAla announces that its novel P1 molecule has been accepted by USPTO to its accelerated "Patent Prosecution Highway"
MAPS Welcomes New Investors, Name Change for MAPS Public Benefit Corporation
January 05, 2024 08:01 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS shares ownership of Lykos with mission-aligned investors, will continue to advance psychedelic research, change drug policy, and shape culture